News from the FDA/CDC
News from the FDA/CDC
Ustekinumab becomes second biologic approved for PsA in kids
The approval is based on an extrapolation of data from adult trials in active psoriatic arthritis and adult and pediatric studies in moderate to...
News from the FDA/CDC
Potentially deadly bacteria detected in U.S. soil
“It is unclear how long the bacteria has been in the environment and where else it might be found in the U.S.”
News from the FDA/CDC
FDA grants emergency authorization for Novavax COVID vaccine
Clinical trials found the vaccine to be 90.4% effective in preventing mild, moderate or severe COVID-19.
News from the FDA/CDC
FDA authorizes Pfizer’s COVID booster for kids ages 5 to 11
“The omicron wave has seen more kids getting sick with the disease and being hospitalized, and children may also experience longer-term effects,...
News from the FDA/CDC
Upadacitinib earns FDA approval for ankylosing spondylitis
Janus kinase inhibitor offers oral option for patients who have who have had an insufficient response or intolerance with one or more tumor...
News from the FDA/CDC
CDC panel lists reasons to get second COVID booster
One panelist said she was concerned about the potential for “booster fatigue.”
News from the FDA/CDC
FDA to decide by June on future of COVID vaccines
“We’d love to see an annual vaccination similar to influenza but realize that the evolution of the virus will dictate how we respond in terms of...
News from the FDA/CDC
As FDA OKs another COVID booster, some experts question need
“Is the goal to prevent any symptomatic infection with COVID-19, is the goal to prevent the spread of COVID-19, or is the goal to prevent severe...
News from the FDA/CDC
FDA OKs first condom for anal sex
Though the CDC has long encouraged the use of a condom during anal intercourse, the FDA had not until now deemed this practice safe.
News from the FDA/CDC
Immunocompromised patients should receive fourth COVID shot: CDC
The CDC contacted pharmacies on Jan. 26 to reinforce the message that people with moderate to severe immune suppression should receive a fourth...
News from the FDA/CDC
FDA approves risankizumab (Skyrizi) for psoriatic arthritis
The approval is the second indication for the anti–interleukin-23 monoclonal antibody after clearance for plaque psoriasis was granted in 2019.